Previous 10 | Next 10 |
PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that its Board of Director...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has initiated the first in a series of studies to ...
Iroquois Capital Delivers Open Letter to PharmaCyte Biotech Board of Directors PR Newswire Expresses Disappointment in the Board's Failure to Articulate a Plan to Maximize Shareholder Value Amid Prolonged Product Development Efforts Despite the Company's Strong Cash ...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the management team will be attending the 15th Intern...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that the empty capsule material that comprises its pancrea...
PharmaCyte Biotech (NASDAQ:PMCB) has decided to accelerate preparations for the start of its phase 2b trial in locally advanced, inoperable pancreatic (LAPC) using its CypCaps product, even as clinical hold by the FDA on the trial remains. PharmaCyte's CEO Kenneth Waggoner, said of ...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that PharmaCyte has decided to accelerate preparations for...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today the appointment of Dr. Matthias Löhr to PharmaCyt...
PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed a 24-month product ...
PharmaCyte Biotech press release (NASDAQ:PMCB): Q3 cash on hand of approximately $87M as of January 31, 2022. For further details see: PharmaCyte Biotech reports Q3 results
News, Short Squeeze, Breakout and More Instantly...
PharmaCyte Biotech Inc. Company Name:
PMCB Stock Symbol:
OTCMKTS Market:
PharmaCyte Biotech Inc. Website:
Second external investment in life sciences solidifies previously announced strategy to utilize significant cash position to create additional stockholder value PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 mi...